For all that’s worked in favor of marijuana stocks in recent years, there are plenty of risks. Some of these risks, such as profitability eluding most pot stocks, are readily apparent.
Legalized marijuana has a lot of investors having visions of lots of green. With legalization sweeping across the states, it seems to be a great time to invest in marijuana stocks. Unfortunately, it’s not.
Two of the top 10 most-traded shares in Sweden in January 2018 were Canada marijuana stocks, adding further proof that the marijuana market is growing more global with each passing day.
Anticipation is building for GW Pharmaceuticals (NASDAQ:GWPH) as the biotech prepares to hopefully launch its first product in the U.S. in 2018.
Canadian cannabis company Aphria Inc said on Thursday it was exploring strategic alternatives, including a sale, for its U.S. business, amid tightening enforcement of federal cannabis laws in the country.
Licensed marijuana producer Aphria Inc. announced an agreement Monday to buy medical cannabis firm Nuuvera Inc. in a cash-and-stock deal that it says values the company at $826 million.
A U.S. private equity firm investing exclusively in legal cannabis said on Thursday it had raised more than $100 million in its third round of fundraising, underscoring investor appetite for the burgeoning industry.
Canada’s No. 2 marijuana producer Aurora Cannabis Inc has agreed to buy smaller rival CanniMed Therapeutics Inc for C$1.1 billion ($852 million) as companies jostle to benefit from the country’s legalization of recreational marijuana use later this year.
Investors are betting Canada’s smaller financial firms could see a jump in revenues after they helped fund marijuana companies ahead of the country’s planned legalization of the drug this year.
Canadian marijuana producer Aurora Cannabis Inc (ACB.TO) is in talks with rivals CanniMed Therapeutics Inc (CMED.TO) and Newstrike Resources Ltd (HIP.V) to buy both businesses in a friendly deal that would create the nation’s top weed company, people familiar with the matter told Reuters on Friday.
Aurora Cannabis Inc. (TSX:ACB) and Canopy Growth Corp. (TSX:WEED) are the two frontrunners in the rapidly emerging Canadian cannabis scene, but will these two powerhouses play leapfrog as legalization day comes and goes?
Canadian cannabis stocks fell on Thursday after the U.S. government said it would resume enforcement of federal laws banning marijuana in states that had legalized pot, disrupting a seven-day rally that boosted shares to record highs.
Marijuana companies are higher than ever as California rolls toward recreational legalization. The BI Canada Cannabis Competitive Peers index is having its best day ever as Californians prepare to light up, or eat up, marijuana products starting Jan. 1 at 12 a.m.
Medical marijuana maker CanniMed Therapeutics Inc (CMED.TO) should withdraw a shareholder rights plan adopted to fend off a hostile bid from larger rival Aurora Cannibis Inc ABC.TO, two Canadian regulators have ruled.
Medical marijuana maker Aphria Inc said on Thursday it would invest C$10 million ($7.80 million) in the proposed combination of two recreational marijuana companies to expand its presence in the sector.
Here’s why the marijuana market is so intriguing, how big the opportunity could be, and why these stocks are top stocks to own.
Aurora Cannabis has launched the first ever “hostile” takeover of another ACMPR Licensed Producer of Medical Marijuana. Executive Vice President Cam Battley lays out the case for why CanniMed shareholders should tender their shares to the Aurora bid.
Following market close on Dec. 4, 2017, Aphria Inc. (TSX:APH), an Ontario-based licensed producer of medical cannabis, made headlines when it announced that it had entered into an agreement to be the medical cannabis supplier for Shoppers Drug Mart, a Canadian pharmacy chain.
Canada’s Aurora Cannabis Inc (ACB.TO) said on Monday it increased its stake in Australia-based Cann Group Ltd (CAN.AX) to 22.9 percent from 19.9 percent, its latest move to expand in the cannabis industry.
The first U.S. exchange-traded fund, ETF, to focus on marijuana stocks is launching Dec. 26 — days before California legalizes recreational cannabis use on January 1.
Over the past year, investors have been anxiously following the progression of marijuana stocks such as Canopy Growth Corp, which offer the promise of significant growth from the new, emerging segment of the economy.
If it seems like there’s been a spurt of deals and potential deals going on in the cannabis industry lately, it’s because that’s exactly what’s happening.
Canada’s weed stocks, which have surrendered some of the potent gains that pushed them to record highs this month, face a bumpy ride in 2018 that could purge smaller players, as the country moves to allow recreational use of cannabis in July.
Say hello to the very first marijuana ETF for the U.S. As reported by CNBC, on Oct. 27, ETF Managers Group filed for a new ETF, the Alternative Agroscience ETF.
Not surprisingly, Canadian pot stocks have been the top performers of late, with Canopy Growth Corp. (NASDAQOTH:TWMJF), the now-largest marijuana stock in the world by market cap, leading the charge.
Vancouver-based Aurora Cannabis Inc. said Tuesday that it has made an all-share offer for CanniMed Therapeutics Inc., a fellow Canadian medical marijuana company.
A subsidiary of the New York Stock Exchange launches trading on Dec. 26 for its first-ever marijuana fund, a major step for an industry that’s struggled to access mainstream U.S. financial instruments, even as Canadian markets have kicked off marijuana investment.
At one point, MassRoots was flying high, raising millions of dollars from investors and attempting to become the first cannabis company listed on the Nasdaq.
Manitoba’s the latest province to unveil its plan for marijuana sales and distribution, releasing details Tuesday on how the new industry will operate.
Shares of Canopy Growth Corp. (TSX:WEED) have climbed a stunning 53.8% month over month as of close on November 1. With all of this in mind, has Canopy established itself as the premier cannabis stock for Canadians?
The Auscann Group Holdings Ltd (ASX: AC8) share price had a day to remember on Tuesday. At one stage the medicinal cannabis company’s shares were up as much as 27% before finishing the day 23.5% higher at 52.5 cents.
Shares of Insys Therapeutics, a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy.
Shares of Canadian marijuana company Aphria Inc sank on Tuesday, after the operator of the Toronto Stock Exchange said cannabis companies with U.S. interests would come under heightened scrutiny and could be delisted.
On Oct. 16, 2017, the Board of Directors for MassRoots (OTCQB:MSRT), a marijuana social media platform, ousted Isaac Dietrich as the company’s Chairman and Chief Executive Officer.
The stock of MedReleaf Corp. has recently outperformed those of other top marijuana stock players in Canada, and there could be further price gains going forward after the recently listed cannabis firm has found its footing and stopped the earlier quarterly revenue declines.
Canada’s biggest medical cannabis producers are seeing their stock prices rise after the federal government announced a plan to levy a one dollar per gram tax on recreational marijuana sales.
Marijuana companies should be careful in overselling how much growth will be achieved or what the prospects will look like for the industry. There is a recent example that cannabis investors would be wise to review, and that’s what happened with Freshii Inc..
After the company announced it will tap investors for money to fuel R&D (research and development) and pre-commercialization efforts for its Dravet syndrome drug, shares in Zogenix (NASDAQ: ZGNX) are rallying 10% at 2 p.m. EDT today.
Toronto-based Trellis, which provides cannabis inventory management software, has raised $2.5 million led by Casa Verde Capital.
Marijuana stock investors are going to have to keep their eyes on the following two critical data points for each and every marijuana stock they’re considering buying, or that they already own.
New Brunswick recently announced how the province will manage the sale and distribution of marijuana. New Brunswick has also signed deals with Canopy Growth Corp. (TSX:WEED) and another company listed on the venture exchange.
The Ontario government announced September 8 that the LCBO will oversee the retail sale of cannabis in Ontario through standalone stores and an e-commerce site.
Almost three months after the initial public offering (IPO) of MedReleaf Corp. (TSX:LEAF), shares have yet to do much in either direction. The company, which came to market in what was then described as a “botched IPO,” fell quickly out of the gate from its IPO price.
Arizona’s attorney general is suing Insys Therapeutics over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company’s shares to tumble 18.5% in August, according to S&P Global Market Intelligence.
Undoubtedly, a reversal in the federal government’s laxness on pot would be terrible news for marijuana stock investors, but not every last company would be decimated. One marijuana stock could still thrive, even with Jeff Sessions waving the metaphorical sword at the pot industry: Scotts Miracle-Gro.
With prices for many major Canadian cannabis stocks such as Canopy Growth Corp., Aphria Inc., and Aurora Cannabis Inc. trading sideways over the past few months, investors are now wondering which direction stocks will move from here, and what the long-term play with this industry is overall.
Canopy Growth Corp. (TSX:WEED) was the first cannabis stock to the market and quickly captured the attention of traders and risk-taking growth investors alike. As a result, shares of Canopy skyrocketed 300% in a span of just a few months last year.
It seems as though news of recalls related to specific batches of bad marijuana from licensed Canadian producers has been coming in more frequently than marijuana investors and consumers would like to see.
The storied Silicon Valley venture firm Benchmark Capital has launched a slew of tech companies: Twitter, Uber, Snapchat, Instagram. Now its search for the next big thing has led it to … pot.
Whereas most weed businesses are working harder than ever to increase their grow capacity, Cronos Group is a company that’s trying to work smarter. Based in Canada, Cronos Group is an investment firm that primarily invests in Canadian-based pot companies involved in Canada’s medical-marijuana industry.